Samsung Biologics Co., Ltd. (SSBIOLOGICS) income statement
KSC · Healthcare · Biotechnology · 5,455 employees · CEO John Chongbo Rim
- Price
- $1,001 -0.1%
- Market cap
- $48.5B
- Enterprise value
- ₩65.5T Data as of 2026-11-21
- Last report
- Q3 '26 filed 2026-09-30
- Next report
- 2027-01-27 EPS est. ₩11,137.25
Samsung Biologics Co., Ltd. (SSBIOLOGICS) reported revenue of ₩1.49T for Q3 '26 (-10.2% year on year), operating income of ₩640B (43.0% of revenue) and net income of ₩391B. Over the last four quarters revenue was ₩4.38T.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₩1.07T | ₩947B | ₩1.16T | ₩1.19T | ₩1.26T | ₩1.3T | ₩1.29T | ₩1.66T | ₩309B | ₩1.26T | ₩1.32T | ₩1.49T | |
| Cost of revenue | ₩551B | ₩536B | ₩509B | ₩659B | ₩601B | ₩543B | ₩586B | ₩645B | ₩223B | ₩555B | ₩599B | ₩752B | |
| Gross profit | ₩522B | ₩410B | ₩648B | ₩528B | ₩655B | ₩755B | ₩704B | ₩1.01T | ₩86B | ₩702B | ₩722B | ₩1.49T | |
| Research & development | ₩22.4B | ₩24.6B | ₩26.6B | ₩29.6B | ₩63.9B | ₩87.1B | ₩40.3B | ₩107B | ₩0 | ₩38.2B | ₩0 | ₩0 | |
| General & administrative | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | ₩98.4B | |
| Other operating expenses | ₩886M | ₩1.71B | ₩6.12B | ₩1.61B | ₩1.7B | ₩1.67B | ₩8.78B | ₩598M | -₩5.08B | ₩578M | ₩135B | ₩752B | |
| Operating expenses | ₩172B | ₩189B | ₩213B | ₩190B | ₩329B | ₩268B | ₩228B | ₩286B | -₩5.08B | ₩122B | ₩135B | ₩850B | |
| Operating income | ₩350B | ₩221B | ₩435B | ₩339B | ₩326B | ₩487B | ₩476B | ₩729B | ₩91.1B | ₩581B | ₩586B | ₩640B | |
| Interest income | ₩25.6B | ₩22.4B | ₩14.4B | ₩13.3B | ₩13.7B | ₩13.2B | ₩12.4B | ₩13.4B | ₩7.08B | ₩14B | ₩13.3B | ₩19.3B | |
| Interest expense | ₩19.5B | ₩16.1B | ₩8.18B | ₩1.73B | ₩24.1B | ₩9.92B | ₩8.26B | ₩10.7B | ₩285M | ₩7.15B | ₩8.78B | ₩9.46B | |
| Other non-operating income (gains on investments, FX ...) | -₩25.2B | -₩34.9B | -₩38.6B | ₩45.9B | -₩72.4B | -₩22.6B | ₩58.4B | -₩48.9B | -₩353B | -₩67B | ₩0 | ₩108B | |
| Total non-operating income | ₩5.74B | ₩18.8B | ₩30.4B | -₩47.6B | ₩48.4B | ₩12.7B | -₩66.7B | ₩38.2B | ₩352B | ₩59.8B | -₩1.8B | -₩108B | |
| Income before tax | ₩356B | ₩240B | ₩465B | ₩291B | ₩374B | ₩499B | ₩409B | ₩767B | ₩443B | ₩641B | ₩585B | ₩532B | |
| Income tax | ₩65B | ₩60.7B | ₩147B | ₩26.5B | ₩52.5B | ₩124B | ₩84.5B | ₩193B | ₩103B | ₩171B | ₩154B | ₩141B | |
| Net income | ₩291B | ₩179B | ₩318B | ₩264B | ₩321B | ₩376B | ₩324B | ₩574B | ₩510B | ₩469B | ₩431B | ₩391B | |
| EPS (basic) | ₩6,279.49 | ₩3,874.66 | ₩6,869.42 | ₩5,713.18 | ₩6,945.06 | ₩8,112.89 | ₩7,007.55 | ₩12,409.00 | ₩11,028.00 | ₩10,148.00 | ₩9,304.19 | ₩8,391.77 | |
| EPS (diluted) | ₩6,279.49 | ₩3,874.66 | ₩6,869.42 | ₩5,713.18 | ₩6,945.06 | ₩8,112.89 | ₩7,007.55 | ₩12,409.00 | ₩11,028.00 | ₩10,148.00 | ₩9,304.19 | ₩8,391.77 | |
| Shares (basic, weighted) | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.2M | 46.2M | 46.3M | 46.6M | |
| Shares (diluted, weighted) | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.3M | 46.2M | 46.2M | 46.3M | 46.6M | |
| Depreciation & amortization | ₩142B | ₩143B | ₩148B | ₩157B | ₩151B | ₩163B | ₩178B | ₩179B | ₩113B | ₩94.6B | ₩112B | ₩111B | |
| EBITDA | ₩517B | ₩400B | ₩621B | ₩450B | ₩549B | ₩673B | ₩595B | ₩957B | ₩557B | ₩742B | ₩699B | ₩532B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₩295B | ₩465B | ₩536B | ₩702B | ₩1.16T | ₩1.57T | ₩3T | ₩3.69T | ₩3.5T | ₩4.56T | |
| Cost of revenue | ₩274B | ₩342B | ₩405B | ₩471B | ₩696B | ₩783B | ₩1.56T | ₩1.92T | ₩1.82T | ₩2.07T | |
| Gross profit | ₩20.5B | ₩122B | ₩131B | ₩231B | ₩469B | ₩785B | ₩1.44T | ₩1.77T | ₩1.68T | ₩2.48T | |
| Research & development | ₩0 | ₩0 | ₩0 | ₩48.5B | ₩68.1B | ₩76B | ₩160B | ₩81.6B | ₩36.7B | ₩37.2B | |
| Other operating expenses | ₩1.2B | ₩997M | ₩1.56B | ₩1.66B | ₩1.79B | ₩1.8B | ₩7.45B | ₩10.3B | ₩4.69B | ₩5.97B | |
| Operating expenses | ₩50.9B | ₩56.3B | ₩74.9B | ₩138B | ₩176B | ₩248B | ₩458B | ₩657B | ₩360B | ₩415B | |
| Operating income | -₩30.4B | ₩66B | ₩55.7B | ₩92.1B | ₩293B | ₩537B | ₩984B | ₩1.11T | ₩1.32T | ₩2.07T | |
| Interest income | ₩3.64B | ₩9.95B | ₩9.65B | ₩17.2B | ₩13.1B | ₩9.66B | ₩53.3B | ₩95.7B | ₩63.8B | ₩46B | |
| Interest expense | ₩19.3B | ₩5.68B | ₩15.8B | ₩25.6B | ₩16.1B | ₩14.7B | ₩64.1B | ₩81.6B | ₩50.1B | ₩29.2B | |
| Other non-operating income (gains on investments, FX ...) | ₩0 | ₩0 | ₩0 | ₩0 | ₩0 | -₩38.7B | -₩89.5B | -₩87.9B | -₩114B | -₩78.6B | |
| Total non-operating income | -₩200B | -₩182B | ₩247B | ₩63.4B | -₩27.3B | ₩24B | ₩25.4B | ₩6.31B | ₩63.5B | ₩49.4B | |
| Income before tax | -₩231B | -₩116B | ₩303B | ₩155B | ₩266B | ₩561B | ₩1.01T | ₩1.12T | ₩1.38T | ₩2.12T | |
| Income tax | -₩54.1B | -₩19B | ₩78.9B | -₩47.5B | ₩25B | ₩168B | ₩211B | ₩262B | ₩345B | ₩504B | |
| Net income | -₩177B | -₩97B | ₩224B | ₩203B | ₩241B | ₩394B | ₩798B | ₩858B | ₩1.08T | ₩1.78T | |
| EPS (basic) | -₩4,739.12 | -₩2,230.35 | ₩5,152.93 | ₩4,665.54 | ₩5,540.93 | ₩9,050.12 | ₩17,592.00 | ₩18,528.00 | ₩23,402.00 | ₩38,588.00 | |
| EPS (diluted) | -₩4,739.12 | -₩2,230.35 | ₩5,152.93 | ₩4,665.54 | ₩5,540.93 | ₩9,050.12 | ₩17,576.00 | ₩18,528.00 | ₩23,402.00 | ₩38,588.00 | |
| Shares (basic, weighted) | 37.3M | 43.5M | 43.5M | 43.5M | 43.5M | 43.5M | 45.4M | 46.3M | 46.3M | 46.2M | |
| Shares (diluted, weighted) | 37.3M | 43.5M | 43.5M | 43.5M | 43.5M | 43.5M | 45.4M | 46.3M | 46.3M | 46.2M | |
| Depreciation & amortization | ₩60.1B | ₩69.9B | ₩91.5B | ₩133B | ₩144B | ₩162B | ₩308B | ₩490B | ₩599B | ₩634B | |
| EBITDA | ₩29.7B | ₩136B | ₩147B | ₩225B | ₩437B | ₩738B | ₩1.38T | ₩1.69T | ₩2.03T | ₩2.78T |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in KRW.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings.
Data as of 2026-11-21 · Amounts in KRW as reported; price and market cap in USD.